



# The Brazilian Journal of INFECTIOUS DISEASES

[www.elsevier.com/locate/bjid](http://www.elsevier.com/locate/bjid)



## Original article

# Enterobacteriaceae resistant to third generation cephalosporins upon hospital admission: risk factors and clinical outcomes<sup>☆</sup>



Mirian Cristina Oliveira<sup>a,\*</sup>, Clara Rodrigues Alves Oliveira<sup>a</sup>,  
Karine Valéria Gonçalves<sup>a</sup>, Marciléa Silva Santos<sup>a</sup>, Amanda Cristina Silva Tardelli<sup>b</sup>,  
Vandack Alencar Nobre Jr.<sup>a</sup>

<sup>a</sup> Graduate Program in Infectious Diseases and Tropical Medicine, Internal Medicine Department, School of Medicine and University Hospital – Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil

<sup>b</sup> Laboratory of Microbiology, University Hospital – Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil

## ARTICLE INFO

### Article history:

Received 20 July 2014

Accepted 30 January 2015

Available online 16 April 2015

### Keywords:

Enterobacteriaceae

Third generation cephalosporins

Risk factors

Antibiotic resistance

## ABSTRACT

**Objectives:** Evaluate risk factors and clinical outcomes of infections caused by Enterobacteriaceae resistant to third-generation cephalosporins present in samples collected upon hospital admission.

**Methods:** Risk factors were evaluated using a 1:2 ratio case–control study. Influence of resistance on the appropriateness of antibiotic therapy, length of stay, and hospital mortality were prospectively evaluated. Characteristics independently associated with the presence of resistant enterobacteria were assessed by logistic regression.

**Results:** Enterobacteria resistant to third-generation cephalosporins were quite common (26.0%). Male gender (OR: 2.66; 95% CI, 1.17–5.06;  $p=0.019$ ), invasive prosthesis (OR: 3.79; 95% CI, 1.29–11.08;  $p=0.015$ ), previous use of cephalosporins (OR: 2.77; 95% CI, 1.10–6.97;  $p=0.029$ ) and hospitalization in the last 6 months (OR: 5.33; 95% CI, 2.29–12.44;  $p<0.001$ ) were independently associated with the presence of these microorganisms. These bacteria were associated with higher frequency of inappropriate antimicrobial therapy, worse clinical response, and longer length of stay. Finally, older age, admission to the ICU, and site of infection other than urinary tract were independently associated to higher hospital mortality.

**Conclusions:** Risk factors identified in this study may help in the choice of empirical antibiotic therapy for infected patients suspected of harboring these bacteria and in the early implementation of measures to avoid the spread of these bacteria in the hospital environment.

© 2015 Elsevier Editora Ltda. All rights reserved.

<sup>☆</sup> This study was partially supported by the Fundação de Amparo à Pesquisa do Estado de Minas Gerais – FAPEMIG (APQ-00823-11).

\* Corresponding author at: Graduate Program in Infectious Diseases and Tropical Medicine, Internal Medicine Department, School of Medicine and University Hospital – Universidade Federal de Minas Gerais, Av Alfredo Balena, 190, Santa Efigênia, CEP: 30130-100 Belo Horizonte, MG, Brazil.

E-mail address: [miriancoliveira@yahoo.com.br](mailto:miriancoliveira@yahoo.com.br) (M.C. Oliveira).

<http://dx.doi.org/10.1016/j.bjid.2015.01.006>

1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.

## Introduction

*Enterobacteriaceae* are responsible for a wide variety of nosocomial and community-acquired infections.<sup>1,2</sup> Given their versatility, low toxicity, and broad spectrum of action,  $\beta$ -lactam antibiotics, such as the third generation cephalosporins, are the main choice for the treatment of infections caused by these microorganisms.<sup>3</sup> However, along with their overuse, a decrease in the effectiveness of these compounds has been observed in recent years.<sup>4</sup> In *Enterobacteriaceae*, antibiotic resistance due to the production of extended-spectrum  $\beta$ -lactamase (ESBL-E) and overexpression of AmpC cephalosporinase (AmpC-E) is cause for great concern and produce a significant impact both on empirical and definitive therapy.<sup>5,6</sup> Moreover, this resistance may lead to delays in the onset of effective antimicrobial therapy, with consequent impact on clinical results, and higher mortality rate.<sup>7</sup>

Many studies have attempted to determine the risk factors for nosocomial infections caused by *Enterobacteriaceae* resistant to third-generation cephalosporins, and more recently, some publications have addressed those cases identified at the time of hospital admission.<sup>7-9</sup> Our aim was to determine the frequency, risk factors, and the impact on clinical outcome of the presence of *Enterobacteriaceae* resistant to third-generation cephalosporins isolated in samples collected within the first 48 h of hospitalization of patients admitted to a university hospital.

## Material and methods

### Study setting and subjects

This two-phase study was conducted from August 2011 to July 2012, in a 501-bed University Hospital of Minas Gerais, Brazil. Firstly, a 1:2 ratio case-control protocol was run, in order to identify characteristics associated with colonization or infection by resistant *Enterobacteriaceae* in samples obtained during the first 48 h of hospitalization. Thereafter, in the second phase of the study, the included patients were followed up in order to identify the impact of these microorganisms in some clinical endpoints. Patients at least 18 years old, whose culture requested by the attending physician grew enterobacteria in samples collected in pre-specified days after hospitalization were assessed for potential inclusion. Patients with enterobacteria resistant to carbapenems were excluded from the study. All included patients lived in the metropolitan area of Belo Horizonte, Minas Gerais state.

Eligible patients were screened in the emergency service of our hospital and categorized into one of two groups: (i) cases, referring to those colonized or infected by *Enterobacteriaceae* resistant to third-generation cephalosporins and, (ii) controls, patients colonized or infected by *Enterobacteriaceae* susceptible to third-generation cephalosporins. For each case included in the study, two controls were selected sequentially on the same day. Each patient was included in the study only once.

Patients were further categorized as (i) infected patients, if there was a clinical suspicion of active infection

leading to prescription of antibiotic therapy, and (ii) colonized patients, if there was no clinical suspicion of infection or if the enterobacteria were isolated from surveillance samples. Surveillance samples were samples collected at the time of hospital admission via swabs, as a routine procedure in patients transferred from other hospitals aiming at detecting the presence of patients colonized with multidrug-resistant bacteria.

### Study procedures and definitions

Demographic, clinical, and epidemiological data were collected using a dedicated case report form. Data was obtained from interviews and by consulting electronic and printed records. The following variables were collected: age, sex, microbiological data, site of infection, presence of comorbidities (diabetes, chronic renal failure, liver failure, solid tumor, malignant hematological disease, heart failure, and others), known immunosuppression (HIV infection, neutropenia with PMN <500 cells/mm<sup>3</sup>, use of corticosteroids in doses above 15 mg/day of prednisone or equivalent, use of other immunosuppressive drugs), hospitalization and previous use of antibiotics, performance of invasive procedures in the last four weeks, use of invasive prosthesis, presence of stoma, recurrent urinary tract infection (UTI), adequacy of initial empiric antibiotic treatment (only for infected patients), hospitalization at the intensive care unit (ICU), response to the antibiotic therapy, all-cause hospital mortality, and hospital length of stay.


Recurrence of urinary tract infection (UTI) was defined as the development of two or more documented episodes in the last six months. For the subgroup of infected patients, empirical treatment was considered adequate when an antimicrobial regimen included an active antibiotic against the isolated enterobacteria, and was initiated at the recommended dose in the first 24 h after sample collection. Inadequate antimicrobial treatment included absence of antimicrobial agents indicated for a specific class of microorganisms and administration of an antimicrobial agent to which the isolated microorganism was resistant.<sup>10</sup>

In this subset of patients, clinical response to the antimicrobial treatment was classified as: "complete or partial resolution", referring to the patients who presented total or partial improvement of fever, leukocytosis and clinical signs of infection, and "therapeutic failure or uncertain result", for those who, respectively, showed no decrease in these parameters at all or persisted with symptoms and signs that were not clearly attributable to infection.<sup>11</sup>

For the infected patients clinical outcomes were ICU admittance during follow-up, all-cause hospital mortality, and length of hospital stay.

### Microbiological analysis

Bacterial identification and antimicrobial susceptibility testing, including production of  $\beta$ -lactamases, were carried out in accordance with the recommendations of the *Clinical and Laboratory Standards Institute (CLSI)*.<sup>12</sup> Identification and ESBL



**Fig. 1 – Flowchart presenting the procedures for inclusion in the study.**

production were confirmed by using the API 20E® and Vitek II® systems (both from bioMérieux).

### Statistical analysis

Categorical variables were compared by using the Pearson's chi-square test (or Fischer's exact test, as indicated), and presented with the corresponding 95% confidence intervals (CI). Continuous variables were compared using Student's t-test. In cases of non-normal distribution of quantitative variables, non-parametric tests were used, such as Mann–Whitney U test.

Non-conditional multivariate logistic regression analysis was conducted to determine the independent risk factors associated with the presence of resistant enterobacteria. All variables presenting the  $p$ -value  $<0.20$  in univariate analysis were included in the multivariate model. Furthermore, the independent risks factors associated with in-hospital death were investigated in a multivariate analysis excluding the colonized patients. Using the same criteria described above ( $p$ -value  $<0.20$  in the univariate analysis), the following variables were include in this analysis: age, presence of two or more comorbidities, presence of UTI, admittance to ICU, inappropriate empirical antibiotic therapy, and presence of resistant enterobacteria (cases). For the multivariate models, backward method was used, and the Hosmer and Lemeshow test was applied to assess the models' adequacy.

Finally, to evaluate the impact of the infections caused by enterobacteria resistant to third-generation cephalosporins on hospital length of stay, a Cox proportional hazards analysis was conducted. The variable "age" was included as a binary variable (greater than or less than 50 years). Discharges by death were censored. For all analyses, a two-tailed value of

$p < 0.05$  was considered significant. Statistical analyses were performed by using SPSS version 16.0 software.

## Results

### Selection of studied patients

During the study period, 238 adult patients had one or more *Enterobacteriaceae* isolated from samples collected in the first 48 h after hospital admission. Of this total, 62 (26.0%) patients had *Enterobacteriaceae* resistant to third-generation cephalosporins. The flowchart presenting the inclusion procedures is summarized in Fig. 1.

### Demographic characteristics and comorbidities

Results of univariate analysis are shown in Table 1. Case patients had higher mean age ( $56.7 \pm 19.1$  vs.  $46.9 \pm 19.6$ ,  $p = 0.001$ ), were more frequently male (53.2% vs. 25.8%;  $p < 0.001$ ), and usually presented two or more comorbidities (50.0% vs. 34.7%,  $p = 0.044$ ). Specifically, heart failure (HF) was the only comorbidity significantly more frequent among cases (17.7% vs. 7.3%,  $p = 0.031$ ).

### Microbiological results

Taking into account the whole sample of patients, there was a predominance of infected patients (81.7%); however, there was significantly more colonized individuals among cases as compared to controls (25.8% vs. 12.9%,  $P = 0.028$ ). Out of all cases, 14.5% were detected through surveillance cultures. For both groups, UTI was the most common site of infection (83.1% in the control group vs. 59.7% in cases,  $p < 0.001$ ). A significant

**Table 1 – Demographic and clinical characteristics of patients in whom there was isolation of Enterobacteriaceae in samples collected in the first 48 h of hospitalization.**

Variables	Casesn = 62	Controlsn = 124	p-value	OR (95% CI)
Male, n (%)	33 (53.2)	32 (25.8)	<0.001	3.27 (1.72–6.21)
Age, years, mean (SD)	56.7 (19.1)	46.9 (19.6)	0.001	
<b>Comorbidities</b>				
Diabetes mellitus, n (%)	14 (22.4)	24 (19.4)	0.607	1.22 (0.58–2.56)
Chronic renal failure, n (%)	3 (4.8)	4 (3.2)	0.586	1.53 (0.33–7.04)
Liver failure, n (%)	3 (4.8)	3 (2.4)	0.379	2.05 (0.40–10.47)
Solid Tumor, n (%)	22 (35.5)	36 (29.0)	0.371	1.34 (0.70–2.57)
Malignant hematological disease, n (%)	3 (4.8)	4 (3.2)	0.586	1.53 (0.33–7.04)
Heart Failure, n (%)	11 (17.7)	9 (7.3)	0.031	2.73 (1.07–6.99)
Presence of 2 or more comorbidities	31 (50.0)	43 (34.7)	0.044	1.88 (1.01–3.50)
<b>Coexisting conditions</b>				
Transplant	4 (6.5)	10 (8.1)	0.694	0.79 (0.24–2.61)
Immunosuppression, n (%)	19 (30.6)	30 (24.2)	0.346	1.38 (0.70–2.73)
Immunosuppressive drugs, n (%)	16 (25.8)	26 (21.0)	0.457	1.31 (0.64–2.68)
HIV, n (%)	2 (3.2)	2 (1.6)	0.475	2.03 (0.28–14.79)
Primary site of infection			<0.001	
Urinary tract, n (%)	37 (59.7)	103 (83.1)		
Respiratory tract, n (%)	2 (3.2)	4 (3.2)		
Bloodstream, n (%)	2 (3.2)	6 (4.8)		
Skin and soft tissue, n (%)	6 (9.7)	6 (4.8)		
Other sites, n (%)	6 (9.7)	5 (4.0)		
<b>Severity on admission (Manchester)</b>				
Orange or red risk rating, n(%)	21 (33.9)	38 (30.6)	0.656	1.16 (0.61–2.22)

difference was observed in the frequency of species of *Enterobacteriaceae* between the groups ( $p < 0.001$ ). *Escherichia coli* was the most frequently species isolated from the controls (79.0%) whereas in the cases prevailed *Klebsiella pneumoniae* (30.6%) with *E. coli* (30.6%). *Enterobacter* sp. and *Serratia marcescens* were isolated only from cases (24.2% and 6.0%, respectively).

#### Risk factors for Enterobacteriaceae resistant to third-generation cephalosporins

The univariate analysis testing the variables associated with the presence of *Enterobacteriaceae* resistant to third-generation cephalosporins is summarized in Table 2. The composite presence of invasive prosthesis or tunneled catheters and presence of stoma were significantly more frequent among cases than controls. The main types of stoma observed in these patients were cystostomy (41.2%), colostomy (23.5%), and tracheostomy (17.6%). Finally, previous contact with health care services (performance of invasive procedures and/or prior hospitalization) and previous use of antibiotics were also more frequent in patients with resistant *Enterobacteriaceae*.

Previous use of cephalosporins in last 90 days, presence of invasive prosthesis or tunneled catheters, hospitalization in last six months, and male gender were independently associated with the presence of *Enterobacteriaceae* resistant to third generation cephalosporins as shown in Table 3.

#### Impacts on clinical outcome

We prospectively tested the impact of the presence of enterobacteria resistant to third-generation cephalosporins on some clinical endpoints (Table 4). Inappropriate empirical

antibiotic therapy was significantly higher among cases (73.3% vs. 10.3%,  $p < 0.001$ ). Moreover, patients with resistant *Enterobacteriaceae* were more often admitted to the ICU ( $p = 0.003$ ), had worse clinical response to the antimicrobial therapy ( $p = 0.029$ ), and had higher length of stay ( $p < 0.001$ ). Although the death rate was higher among cases (21% vs. 10.5%), this difference did not quite reach statistical significance ( $p = 0.052$ ).

As shown in Table 5, six variables were associated with death during hospitalization in univariate analysis, but seven variables reached criteria to be included in the multivariate model ( $p < 0.20$ ). From these, only increasing age, hospitalization at the ICU, and a primary site of infection other than UTI proved to be independently associated to all-cause hospital mortality.

Finally, to be older than 50 years (HR: 1.63; 95% CI: 1.18–2.27;  $p = 0.003$ ) and presence of *Enterobacteriaceae* resistant to third generation cephalosporins (HR: 2.31; 95% CI: 1.59–3.34;  $p < 0.001$ ) were independently associated with longer length of stay.

## Discussion

In this study, we demonstrated that the presence of *Enterobacteriaceae* resistant to third generation cephalosporins was quite common (26%) in cultures obtained in the first 48 h of hospitalization of adult patients admitted to a university hospital in Brazil. The presence of invasive prosthesis or tunneled catheters, previous use of cephalosporins, hospitalization in the last six months, and be male proved to be risk factors independently associated with the presence of these bacteria. Also, the presence of resistant enterobacteria was associated with

**Table 2 – Univariate analysis of risk factors for patients with isolation of Enterobacteriaceae resistant to third-generation cephalosporins in the first 48 h of hospitalization.**

Risk factor	Cases n=62	Controls n=124	p-value	OR (95% CI)
Patient transferred from another hospital, n (%)	10 (16.4)	14 (11.3)	0.331	1.54 (0.64–3.70)
Invasive prosthesis or tunneled catheters, n (%)	24 (44.4)	21 (17.4)	<0.001	3.81 (1.87–7.78)
Stoma	11 (19.0)	6 (4.8)	0.002	4.60 (1.61–13.16)
Recurrence of UTI	18 (35.3)	27 (22.7)	0.088	1.86 (0.91–3.81)
<b>Previous contact with health care services</b>				
Invasive procedures	24 (40.7)	20 (16.3)	<0.001	3.53 (1.74–7.16)
Prior hospitalization in the last 6 months	33 (60.0)	24 (20.3)	<0.001	5.88 (2.91–11.85)
Prior hospitalization in ICU in the last 6 months	12 (22.6)	11 (9.3)	0.018	2.85 (1.17–6.96)
<b>Previous use of antimicrobials</b>				
Last 90 days				
All	39 (73.6)	56 (47.1)	0.001	3.13 (1.54–6.37)
Cephalosporins	15 (28.3)	14 (11.8)	0.007	2.96 (1.31–6.710)
Quinolones	11 (21.2)	17 (14.3)	0.264	1.61 (0.69–3.73)
β-lactam/β-lactamase inhibitor	8 (15.1)	10 (8.4)	0.186	1.94 (0.72–5.23)
Last 12 months	38 (76.0)	41 (43.6)	<0.001	4.09 (1.90–8.81)

**Table 3 – Independent risk factors for the isolation of Enterobacteriaceae resistant to third generation cephalosporins in samples collected in the first 48 h of hospitalization.**

Variable	Coefficient (β)	OR (95% CI)	p-value
Male	0.980	2.66 (1.17–6.06)	0.019
Previous use of cephalosporins in last 90 days	1.333	3.79 (1.29–11.08)	0.015
Presence of invasive prosthesis or tunneled catheters	1.022	2.77 (1.10–6.97)	0.029
Hospitalization in the last 6 months	1.675	5.33 (2.29–12.44)	<0.001

**Table 4 – Clinical impact of the presence of Enterobacteriaceae resistant to third generation cephalosporins in samples collected within the first 48 h of hospitalization.<sup>a</sup>**

Clinical endpoints	Cases	Controls	p-value
Inappropriate empirical antibiotic therapy (%)	73.3	10.3	<0.001
Clinical response			0.029
Complete or partial resolution	30 (62.5)	87 (79.1)	
Therapeutic failure or uncertain result	18 (37.5)	23 (20.9)	
Length of stay, days, median (25–75)	13 (4.75–31.0)	5 (1.25–9.75)	<0.001
Hospitalization in UCI	26 (44.1)	28 (22.6)	0.003
Hospital discharge condition (death), n (%)	13 (21.0)	13 (10.5)	0.052

<sup>a</sup> Analyses restricted to the subgroup of infected patients (46 cases and 108 controls).

**Table 5 – Factors associated with death during hospitalization.**

Variable	Deceased	Survivors	p-value Univariate	OR (95% CI)	p-value Multivariate
Age, years, average (SD)	62.1 (17.8)	48.7 (20.0)	0.002	1.03 (1.00–1.05)	<0.001
Presence of 2 or more comorbidities (%)	60.0	36.9	0.041	NS	NS
Infection site other than UTI	82.2	56.0	0.007	3.20 (1.12–9.26)	0.030
Immunosuppression	36.0	25.6	0.284	NS	NS
Admission to ICU	72.0	18.8	<0.001	8.53 (3.08–23.66)	<0.001
Inappropriate empirical antibiotic therapy (%)	48.0	25.2	0.022	NS	NS
Enterobacteriaceae resistant to third generation cephalosporins (cases) (%)	48.0	26.4	0.030	NS	NS
Enterobacteriaceae other than E. coli	56.0	24.9	0.059	NS	NS

NS, non-significant.



inadequate empirical antibiotic therapy and longer hospital stay.

In recent years, the frequency of *Enterobacteriaceae* resistant to third generation cephalosporins has increased and disseminated in the hospital environment<sup>4,13-15</sup> and more recently in non-hospital settings.<sup>5,6,16,17</sup> In Brazil, most studies conducted up to now determined the frequency and risk factors associated with these pathogens in patients with nosocomial infections.<sup>18,19</sup> The frequency of *Enterobacteriaceae* resistant to third generation cephalosporins in samples obtained during the first 48 h of hospitalization found in this study was considerably high. The rate found in this study is in line with other reports of nosocomial infection rates in small Brazilian hospitals.<sup>20,21</sup> In the few studies conducted in the country with outpatients the ESBL production rates were considerably lower.<sup>22,23</sup> However, in the present study most cases had had recent hospitalizations (68.4%) or were transferred from other hospitals (16.4%), so they could not be considered as community-acquired. Rather, it seems more appropriate to consider them as health care associated infections.

Notwithstanding the country of interest, most studies have pointed to previous exposure to health care settings as risk factor for the presence of ESBL-determined resistance among *Enterobacteriaceae* identified in cultures obtained at the time of hospital admission.<sup>7,24,25</sup> Similarly, this study identified previous hospitalization in the last six months, and presence of invasive prosthesis or tunneled catheters, and previous use of cephalosporins as factors independently associated with the presence of these bacteria. As for the predominance of male patients, other studies also demonstrated an increased frequency of ESBL-producing *Enterobacteriaceae* among men,<sup>9,24,26,27</sup> but nonetheless this issue remains controversial.<sup>8,28,29</sup> According to Behar<sup>30</sup> the discrepancies are related to methodological differences between the studies, especially the selection of the control group, as well as differences in infection presentation and antibiotics prescribing patterns between genders (e.g., women have UTI more often).

In this study, the presence of resistant *Enterobacteriaceae* was associated with poor clinical outcomes, such as longer length of hospital stay, more frequent hospitalizations at the ICU, and worse clinical response to antibiotic therapy. However, this finding should be interpreted with caution since patients with resistant enterobacteria had higher mean age and more comorbidities. Inadequate antibiotic therapy proved to be significantly more common among cases (73.3% vs. 10.3%), and is one of the possible explanations for less favorable outcomes observed among patients with resistant enterobacteria. Delay to administer appropriate antibiotic therapy correlated with a worse prognosis in several clinical conditions.<sup>26,31,32</sup> Finally, regarding hospital stay, previous reports have shown longer length of stay of patients with infections caused by resistant Gram-negative bacilli (GNB) when compared to infections caused by sensitive GNB.<sup>33</sup>

This study has several limitations. First, it is a single center study, involving a relatively small sample size (186 subjects), which might not be representative of the overall patient population admitted to other hospitals in Brazil or elsewhere. Thus, our findings must be validated in other cohorts, both inside and outside Brazil. The characteristics of the patients studied here prevent us from stating that

the resistant enterobacteria isolated in our patients were community-acquired, being more accurate to consider them as associated with health care facilities. Finally, we evaluated ESBL producers and strains overexpressing AmpC as a single group of enterobacteria resistant to third-generation cephalosporins. The small number of isolates prevented us from performing an analysis separating these two subgroups.

In conclusion, in the present study, consisting of adult patients admitted to a university hospital of high complexity in Brazil, the occurrence of enterobacteria resistant to third-generation cephalosporins is quite common. The recognition of risk factors associated with the presence of these bacteria may have an impact on the choice of empirical antibiotic therapy, particularly in patients with organ dysfunction.

---

### Conflicts of interest

The authors declare no conflicts of interest.

---

### Ethics statement

The study was approved by the Ethics Committee of the institution – COEP UFMG (CAAE-0211. 0.203.000-11) – and has been performed in accordance with the ethical standards laid in the 1964 Declaration of Helsinki and its later amendments. All participants provide their written informed consent to participate.

---

### Acknowledgements

We strongly appreciate the support given by the Microbiology Laboratory's team from Hospital das Clínicas of UFMG, without which this work would not have been possible.

---

### REFERENCES

1. Paterson D. Resistance in gram negative bacteria: *Enterobacteriaceae*. *Am J Infect Control*. 2006;34:S21-8.
2. Coque T, Baquero F, Canton R. Increasing prevalence of ESBL-producing *Enterobacteriaceae* in Europe. *Euro Surveill*. 2008;13:1-11.
3. Bush K. Bench-to-bedside review: the role of  $\beta$ -lactamases in antibiotic-resistant Gram-negative infections. *Crit Care*. 2010;14:224-31.
4. Asensio A, Alvarez-Espejo T, Fernandez-Crehuet JAR, et al. Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant *Enterobacteriaceae* infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. *Euro Surveill*. 2011;16:19983.
5. Pitout JDD, Laupland KB. Extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae*: an emerging public-health concern. *Infection*. 2008;8:159-66.
6. Hawkey PM, Jones AM. The changing epidemiology of resistance. *J Antimicrob Chemother*. 2009;64:i3-10.
7. Rodriguez-Banó J, Picón E, Gijó P, Hernández J, Ruíz M, Penã C. Community-onset bacteremia due to extended-spectrum  $\beta$ -lactamase – producing *Escherichia coli*: risk factors and prognosis. *Clin Infect Dis*. 2010;50:40-8.

8. Saely S, Kaye K, Fairfax M, Chopra T. Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum  $\beta$ -lactamase producing *Klebsiella pneumoniae*. *Am J Infect Control*. 2011;39:390-5.
9. Doernberg SB, Winston LG. Risk factors for acquisition of extended-spectrum  $\beta$ -lactamase producing *Escherichia coli* in an urban county hospital. *Am J Infect Control*. 2012;40:123-7.
10. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest*. 1999;115:462-74.
11. Lautenbach E, Patel J, Bilker W, Edelstein P, Fishman O. Extended-spectrum  $\beta$ -lactamase – producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *Clin Infect Dis*. 2001;32:1162-71.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 21th informational supplement. Approved standard M100-S21. Wayne, PA: CLSI; 2011.
13. Bradford PA. Extended-spectrum  $\beta$ -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev*. 2001;14:933-51.
14. Villegas M, Blanco M, Sifuentes-Osornio J, Rossi F. Increasing prevalence of extended-spectrum-beta lactamase among Gram-negative bacilli in Latin America – 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). *Braz J Infect Dis*. 2011;15:34-9.
15. Hawser S, Bouchillon S, Hoban D, Badal R. Emergence of high levels of extended-spectrum- $\beta$ -lactamase-producing Gram-Negative Bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. *Antimicrob Agents Chemother*. 2009;53:3280-4.
16. Gniadkowski M. Evolution and epidemiology of extended-spectrum  $\beta$ -lactamases (ESBLs) and ESBL-producing microorganisms. *Clin Microbiol Infect*. 2001;7:597-608.
17. Pitout J, Nordmann P, Laupland K, Poirel L. Emergence of *Enterobacteriaceae* producing extended spectrum  $\beta$ -lactamase (ESBLs) in the community. *J Antimicrob Chemother*. 2005;56:52-9.
18. Nogueira K, Higuti I, Nascimento A, Terasawa L. Occurrence of extended-spectrum  $\beta$ -lactamases in *Enterobacteriaceae* Isolated from hospitalized patients in Curitiba, southern Brazil. *Braz J Infect Dis*. 2006;10:390-5.
19. Superti S, Augusti G, Zavascki AP. Risk factors for and mortality of extended-spectrum- $\beta$ -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli* nosocomial bloodstream infections. *Rev Inst Med Trop Sao Paulo*. 2009;51:211-6.
20. Lenhard-Vidal A, Cardoso R, Pádua R, Siqueira V. High prevalence rate of extended-spectrum beta-lactamases (ESBL) among *Enterobacteriaceae* in a small Brazilian public hospital. *Braz J Pharm Sci*. 2011;47:701-7.
21. Santos D, Pimenta F, Alves R, Montalvão D, Santos D, Carmo Filho JR. Extended-spectrum  $\beta$ -lactamases producing *Klebsiella pneumoniae* isolated in two hospitals in Goiânia/Brazil: detection, prevalence, antimicrobial susceptibility and molecular typing. *Braz J Microbiol*. 2008;39:608-12.
22. Minarini L, Poirela L, Trevisani N, Darini A, Nordmann P. Prevalence of community-occurring extended spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* in Brazil. *Curr Microbiol*. 2007;54:335-41.
23. Wollheim C, Guerra I, Conte V, et al. Nosocomial and community infections due to class A extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella* spp. in southern Brazil. *Braz J Infect Dis*. 2011;15:138-43.
24. Ben-Ami R, Rodriguez-Banõ J, Pitout J, et al. A multinational survey of risk factors for infection with extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* in nonhospitalized patients. *Clin Infect Dis*. 2009;49:682-90.
25. Lee J, Kang C, Joo EJ, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae*. *Microb Drug Resist*. 2010;17:267-73.
26. De Rosa FG, Pagani N, Fossati L, et al. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. *Infection*. 2011;39:555-61.
27. Kang CI, Wi YM, Lee MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* strains. *J Clin Microbiol*. 2010;50:312-7.
28. Rodriguez-Banõ J, Alcalá J, Cisneros J, Grill F. Community infections caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Ann Intern Med*. 2008;148:1897-902.
29. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to *Escherichia coli* harbouring extended-spectrum  $\beta$ -lactamases. *J Antimicrob Chemother*. 2006;57:780-3.
30. Behar P, Teixeira P, Fachel J, Kalil A. The effect of control group selection in the analysis of risk factors for extended spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* infections. A prospective controlled study. *J Hosp Infect*. 2008;68:123-9.
31. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended spectrum  $\beta$ -lactamase production in *Enterobacteriaceae* bacteraemia: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2007;60:913-20.
32. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum- $\beta$ -lactamase-producing *Enterobacteriaceae* on hospital admission: derivation and validation of a scoring system. *Antimicrob Agents Chemother*. 2011;55:3485-90.
33. Mauldin P, Salgado C, Hansen I, Durup D, Bosso J. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. *Antimicrob Agents Chemother*. 2010;54:109-15.